Welcome to our dedicated page for Pacific Biosc SEC filings (Ticker: PACB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pacific Biosciences of California, Inc. filings document operating results, governance changes, material agreements, and asset-disposition activity tied to its sequencing business. Recent Form 8-K reports furnish quarterly and full-year financial results, business updates, revenue categories for instruments, consumables, and services, and disclosures related to the company’s long-read sequencing focus.
The filing record also includes proxy materials covering board structure, director elections, executive compensation, equity awards, and stockholder voting matters. Other 8-K disclosures address board appointments, changes in accounting-officer responsibilities, operating responsibility assignments, intellectual-property arrangements, and the completed sale of assets related to short-read DNA sequencing technology.
Christian Henry reported sales of PACB common stock. The filing shows dispositions of 331,793 shares on 02/17/2026 and 140,874 shares on 02/18/2026, with proceeds listed as $522,905.77 and $229,483.75, respectively.
The transactions are reported on Form 144 and reflect restricted-stock sales by an issuer-side holder; timing and amounts are stated in the filing.
Pacific Biosciences of California, Inc. filed a Form S-3 shelf registration dated February 25, 2026 that permits the company to offer, from time to time, common stock, preferred stock, depositary shares, debt securities, warrants, subscription rights, purchase contracts and units. The filing also covers possible resales by selling stockholders; the company will not receive proceeds from resale transactions by those selling stockholders.
The prospectus describes general terms and distribution methods and states that specific offering amounts, prices, terms and expected net proceeds (when applicable) will be provided in prospectus supplements. The company’s common stock trades on Nasdaq under the symbol PACB.
Pacific Biosciences of California, Inc. files its annual report describing a focused long-read sequencing business, a recent asset sale, and ongoing losses and risks. The company designs and manufactures HiFi long-read platforms such as Revio and Vega, plus SMRT Cells, reagents, and application-specific kits for research markets.
On January 30, 2026, PacBio sold intellectual property and other assets related to its short-read DNA sequencing technology to an Illumina affiliate for a $50.0 million cash purchase price, with approximately $48.1 million in net proceeds after a payment direction to former Apton equity holders. It ended 2025 with $49.2 million in backlog, expects most to convert to 2026 revenue, and continues to invest heavily in R&D while recording sizable intangible impairments and restructuring charges.
The company reports recurring net losses and does not expect profitability in 2026, highlighting expense-reduction plans, significant outstanding convertible notes totaling $641.0 million principal, regulatory and competitive pressures in sequencing, and dependence on key personnel as major risks for its future performance.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer Mark Van Oene reported two transactions in the company’s common stock. On February 17, 2026, he sold 129,790 shares in open-market transactions at a weighted average price of $1.576 per share, with individual prices ranging from $1.55 to $1.70. On February 18, 2026, he sold 55,107 shares at a weighted average price of $1.629 per share, with prices ranging from $1.51 to $1.68. The filing states that the reported amount includes shares mandatorily sold to cover tax withholding obligations upon vesting of restricted stock units. After these transactions, he directly owned 1,742,638 shares, which includes 7,500 shares acquired on September 2, 2025 under the company’s 2010 Employee Stock Purchase Plan.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer Christian O. Henry reported open-market sales of company common stock. On February 17, he sold 331,793 shares at a weighted average price of $1.576 per share. On February 18, he sold an additional 140,874 shares at a weighted average price of $1.629 per share.
After these transactions, Henry directly held 2,814,374 shares following the February 17 sale and 2,673,500 shares following the February 18 sale, all as common stock. A footnote explains that the reported shares represent stock mandatorily sold to cover tax withholding obligations related to vesting restricted stock units, and that each sale price shown is a weighted average over a disclosed price range.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer Michele Farmer reported two open-market sales of common stock that were mandatorily executed to cover tax withholding on vesting restricted stock units. On February 17, 2026, Farmer sold 35,215 shares at a weighted average price of $1.576 per share. On February 18, 2026, Farmer sold 14,952 shares at a weighted average price of $1.629 per share, reflecting sale price ranges disclosed in the footnotes. After these tax-related sales, Farmer directly owned 219,092 shares of PACB common stock.
An investor in PACB filed a Rule 144 notice covering the planned sale of 303,739 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on 02/17/2026 on the NASDAQ market.
The filing lists an aggregate market value of 478,692.66 for the shares to be sold and notes that 301,907,431 shares of this class were outstanding. The seller acquired these shares as restricted stock from the issuer on 02/15/2026, with no special payment terms disclosed.
A PACB shareholder filed a notice to sell 606,312 common shares under Rule 144. The planned sale through Morgan Stanley Smith Barney LLC has an aggregate market value of $955,547.71 and is targeted around 02/17/2026 on the NASDAQ exchange.
The shares were acquired as restricted stock from the issuer on 02/15/2026. The notice states that the seller does not know of any undisclosed material adverse information about PACB’s current or prospective operations. PACB had 301,907,431 shares outstanding at the time referenced.
Pacific Biosciences of California, Inc. reported mixed fourth-quarter and full-year 2025 results, combining solid revenue growth with large GAAP losses driven by restructuring and non-cash charges. Q4 2025 revenue rose to $44.6 million from $39.2 million, with full-year 2025 revenue edging up to $160.0 million from $154.0 million. Consumables were a key driver, reaching $21.6 million in Q4 and $82.0 million for 2025, while instrument revenue declined year over year on a full-year basis.
Non-GAAP gross margin improved to 40% for both Q4 and 2025, up from 31% and 33% in the prior-year periods, reflecting better underlying profitability. Yet GAAP net loss widened to $546.4 million for 2025 from $309.9 million, largely due to restructuring, impairment, amortization and the absence of a prior-year $154.4 million debt restructuring gain. Non-GAAP net loss improved to $158.8 million from $228.0 million, and year-end cash, cash equivalents and investments were $279.5 million. The company also completed the sale of short-read sequencing assets for net proceeds of about $48.1 million and highlighted collaborations and product innovations aimed at long-read sequencing growth.
Pacific Biosciences of California, Inc. reported mixed fourth-quarter and full-year 2025 results, combining solid revenue growth with large GAAP losses driven by restructuring and non-cash charges. Q4 2025 revenue rose to $44.6 million from $39.2 million, with full-year 2025 revenue edging up to $160.0 million from $154.0 million. Consumables were a key driver, reaching $21.6 million in Q4 and $82.0 million for 2025, while instrument revenue declined year over year on a full-year basis.
Non-GAAP gross margin improved to 40% for both Q4 and 2025, up from 31% and 33% in the prior-year periods, reflecting better underlying profitability. Yet GAAP net loss widened to $546.4 million for 2025 from $309.9 million, largely due to restructuring, impairment, amortization and the absence of a prior-year $154.4 million debt restructuring gain. Non-GAAP net loss improved to $158.8 million from $228.0 million, and year-end cash, cash equivalents and investments were $279.5 million. The company also completed the sale of short-read sequencing assets for net proceeds of about $48.1 million and highlighted collaborations and product innovations aimed at long-read sequencing growth.
Pacific Biosciences of California, Inc. reported an internal, interim reassignment of executive responsibilities. Effective January 28, 2026, Chief Operating Officer Mark Van Oene now oversees the company’s sales and customer support teams, duties that were previously handled by President and Chief Executive Officer Christian Henry.
At the same time, Mr. Henry has temporarily taken over responsibility for operations and research and development, which had been under Mr. Van Oene. Both executives keep their existing roles and core duties, and the company states there will be no changes to their titles or compensation in connection with this shift.